AlphAIAlphAI — Financial news for AI agents
investing.comOCT 82 min read$HAE

Why is Haemonetics stock surging today?

Haemonetics (HAE) stock surged 16.1% after CSL Plasma committed to rolling out Haemonetics' NexSys PCS devices across all U.S. plasma collection centers by 2027. BTIG raised its price target to $130. HAE hit a 52-week high of $120.72, driven by strong fundamentals and the new agreement.

Original reporting
investing.com
Published Oct 8, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HAEBullishMed
01

Why it matters

The 8‑K filing provides fresh, material information that directly drives the share price movement.

02

Market read

The announcement creates immediate upside for Haemonetics and highlights sector momentum in plasma collection equipment.

03

What to watch

Potential integration risks and reliance on CSL Plasma's execution could temper long‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Haemonetics reported Q1 2027 earnings beat and announced a new full‑network supply agreement with CSL Plasma, prompting a sharp stock rally.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics disclosed a full-network rollout of NexSys PCS devices with CSL Plasma, converting a non‑exclusive agreement into a committed supply for over 300 U.S. centers.

Expected impact

likely continued upward pressure as analysts raise price targets and revenue expectations.

Evidence & confidence

New contract adds $183‑$223 M annual revenue potential; analysts upgraded target to $130, indicating strong market reaction.

Market effects

Sector

Strengthens the medical device sector by highlighting demand for plasma collection technology.

Regional

Positive for U.S. healthcare equipment providers.

Global

Limited to U.S. plasma industry; minimal broader market effect.

Counterpoint

What could challenge this read

The stock may be overbought after a rapid 16% jump; price could correct if rollout timelines slip.

Key entities

  • Company
    Haemonetics

    Medical device maker specializing in blood collection and processing.

  • Company
    CSL Plasma

    Operator of over 300 U.S. plasma donation centers.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 8
$HAEHighAI 8/10

Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers

Haemonetics shares rose 12% after CSL updated its plans to transition all U.S. plasma centers to Haemonetics' NexSys devices by 2027. The deal, initially disclosed in August, was expanded from a partial to a full rollout. Haemonetics' fiscal 2026 revenue was $1.33B, with organic growth at 1.1%. The stock trades at 21x forward earnings, above its 5-year average of 19.1x.

finance.yahoo.com2 min
OCT 8
$HAEHigh

Haemonetics stock surges 17% on CSL Plasma supply deal update

Haemonetics (HAE) shares rose 17% premarket after CSL Plasma updated its supply agreement rollout timeline. CSL expects to complete the rollout of Haemonetics' NexSys PCS devices by the end of 2027. The companies initially agreed in August 2026, with CSL potentially using Haemonetics' devices and disposables in the U.S. Haemonetics did not update its fiscal 2027 guidance.

uk.investing.com2 min